ISCT Asia 2026

Cell and gene therapy manufacturing across Asia-Pacific is moving quickly past early-phase autologous models toward the scalable, allogeneic approaches the field needs to reach more patients, the same shift this year's ISCT Asia program is built around. Cellistic will join that conversation at ISCT Asia 2026, September 2–5, in Singapore.

Fionn Huang, Senior Director Business Development, APAC, represents Cellistic across Asia-Pacific from our and will attend throughout the conference. We look forward to continuing conversations already underway with partners across the region, and to meeting research and industry teams working on the next generation of cell therapy manufacturing.

The iPSC-based Cellistic Echo platform gives allogeneic immune cell programs, including NK, T-cell, and macrophage therapies, a manufacturing-ready starting point: one donor-derived cell line, differentiated and scaled under GMP, in place of a new supply chain for every patient. For programs ready to move from platform to production, that same foundation carries through to full CDMO manufacturing.

If you would like to meet with Fionn Huang in Singapore, please reach out to arrange time.